100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study
Title:
100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study
Author:
Palmieri, C. Linden, H. Birrell, S. Lim, E. Schwartzberg, L.S. Rugo, H.S. Cobb, P. Jain, K. Vogel, C. O'Shaughnessy, J. Johnston, S.R.D. Getzenberg, R.H. Barnette, K.G. Steiner, M. Brufsky, A.M. Overmoyer, B.